Our results demonstrated for the first time that subcutaneous injections of human recombinant FGF19 during 18 days in uremic mice is able (1) to improve fiber size of skeletal muscles (2) reverse glucose intolerance and (3) improve the gene expression of inflammatory markers in the liver. Here, FGF19 is linked to Glucose intolerance.